- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Topical photosensitizers, PDT preferred for AK, BCC tx
When treating actinic keratoses (AK) or basal cell carcinoma (BCC), using a topical photosensitizer like methyl aminolevulinate for photodynamic therapy is less invasive and provides excellent cosmetic results, Rolf-Markus Szeimies, M.D., Ph.D., said yesterday in his presentation on "Methyl Aminolevulinate for Photodynamic Therapy."
When treating actinic keratoses (AK) or basal cell carcinoma (BCC), using a topical photosensitizer like methyl aminolevulinate for photodynamic therapy is less invasive and provides excellent cosmetic results, Rolf-Markus Szeimies, M.D., Ph.D., said yesterday in his presentation on "Methyl Aminolevulinate for Photodynamic Therapy."
He added that cure rates for both AK and BCC lesions are close to those achieved by other therapeutic modalities.
MAL was approved by the U.S. Food and Drug Administration in July 2004 for use in treating AK.
